Clinical Trial Update: Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MRI as a measurement tool for the effect of cabozantinib in patients with castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Casrtation-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Chicago | Conditions: Bone Metastases, Castrate-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-26